Fifty-one percent of 223 children with cancer could have been treated with precision medicine calibrated for certain mutations, but only 7% were given treatment, even though precision medicine may be more beneficial in youths than in adults, according to a study in the European Journal of Cancer. Researchers attributed the low use in childhood cancers to the response of some children to standard treatments, as well as a lack of pediatric trials evaluating drugs that proved effective among adults.
Study: Few youths with cancer receive precision medicine
Sign up for SNMMI SmartBrief
Nuclear medicine and molecular imaging news
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.